Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), SaizenÂ®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children